| Number: | 2008-013-1-700 |
|---|---|
| Start: | 01 June 2008 |
The project under the title “Analogue-based Drug Discovery” has been successfully completed between 2003-2005 and the book, which has been published in 2006 by Wiley-VCH, was well received and all the copies have been sold in 18 months. Based on the positive feedbacks (see eg. M. Cowart, J. Med. Chem. 2006, 49, 4799) a continuation is needed.
The second volume of the book would consist of the following chapters:
I. General Aspects
I-1. Optimizing Therapy by Analogues (J. Fischer, CR. Ganellin, EM. Alapi)
I-2. Analogues and Standalone Drugs (J. Fischer, CR. Ganellin, A. Ganesan, J. Proudfoot)
I-3. Lead and Drug Optimization (J. Fischer and CR. Ganellin)
I-4. Molecular Modeling in ABDD (G. Ferenczy)
I-5. The Impact of Natural Products upon Modern Drug Discovery (A. Ganesan)
I-6. Monoterpenoid Indole Alkaloids (A. Nemes)
I-7. Paclitaxel analogue (P. Erhardt)
I-8. Issues for Patenting of Analogues (S. Smith)
II. Analogue Classes
II-1. Beta2 agonists (G. Gaviraghi)
II-2. M3 muscarinic antagonists (M. Grauert, P. Casarosa, MP. Pieper)
II-3. SSRIs (D. Rotella and WE. Childers)
II-4. Progestogens (Z. Tuba)
II-5. DPP-IV inhibitors (JU. Peters and P. Mattei)
II-6. PDE5 inhibitors (H. Haning and E. Bischoff)
II-7. Serotonin and norepinephrine reuptake inhibitors (M. Abou-Gharbia)
II-8. Anthracyclines (FA. Arcamone)
II-9. Rifampicin analogues (E. Selva and G. Lancini)
III. Case Studies
III-1. Eplerenone (J. Kalvoda and M. De Gasparo)
III-2. Lapatinib (K. Lackey)
III-3. Dasatinib (J. Das)
III-4. Conazoles (J. Heeres, P. Lewi and L. Meerpoel)
III-5. Clevudine (CK. Chu)
III-6. Rasagiline (M. Youdim)
III-7. Liraglutide (LB. Knudsen)
III-8. Tipranavir (S. Thaisrivongs, J. Strohbach, and S. Turner)
The second volume will discuss a broad spectrum of discoveries of anticancer, antifungal, antiviral, cardiovascular, CNS, diuretic, hormonal, respiratory, diabetes type 2 drugs. The majority of the authors, who come from ten different countries, were also involved as inventor.